Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Fulvestrant in ER+/Her2- Advanced Breast Cancer
NCT02953860Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Jul 2017
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 2, open-label trial of enzalutamide in breast cancer, sponsored by University of Colorado Denver. Primary endpoint: Clinical Benefit Rate at 24 weeks. Started Jul 2017; status: completed.
02
Drugs
enzalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02953860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953860.